Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was calming and restoring because the crush of global events continues unabated. Most likely, you anticipated this sort of thing, yes? To cope, as always, we are firing up the coffee kettle and brewing cups of stimulation. Our choice today is cinnamon vanilla nut. Meanwhile, here is a menu of tidbits to help you along on your own journey. Hope all goes well today and please do keep in touch.

Even as companies rush to develop and test vaccines against the new coronavirus, the Bill and Melinda Gates Foundation and the National Institutes of Health are betting that scientists can do even better than what’s now in the pipeline, STAT explains. With Gates and NIH funding, the emerging field of synthetic biology is answering the SOS over Covid-19, aiming to engineer vaccines that overcome these obstacles.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.